Celaid raised an additional 140 million yen from Kobe University Capital and Techno Science

Celaid Therapeutics is pleased to announce that it has received a total of 140 million yen in additional Series A funding from KUC1 Investment Limited Partnership (with GP investment from Kobe University Capital Co., Ltd. and SBI University Venture Support Co., Ltd.) and Techno Science Co., Ltd.

Our company has been part of the Kobe Biomedical Innovation Cluster since July 2022, and in the same year, our business was selected for the Kobe Biomedical Innovation Cluster Gap Fund Grant. We have been actively participating as a member of the Kobe Biomedical Innovation Cluster since then. Recently, we have also initiated a joint research project with the Kobe Biomedical Innovation Cluster (March 28, 2024) and are advancing research and development of cell therapy for ischemic diseases as a further clinical application of hematopoietic stem cells. In recognition of our progress in pipeline development and platform business, as well as our activities in Kobe, we have now received new investment from the fund managed by Kobe University Capital Co., Ltd.

Additionally, we have received further investment from our existing investor, Techno Science Co., Ltd., bringing our total Series A funding to 1.1 billion yen (excluding grants). With this funding, we expect to further accelerate our pipeline development and platform business activities.

As a leading hematopoietic stem cell company originating from a Japanese university, we will continue to promote the development of hematopoietic stem cell pipelines and platform technologies.